RenovoRx Inc is expected to report a third-quarter consensus revenue of $1.06 million and an EPS of -$0.05, while the stock currently trades around $1.33 against an average analyst price target of $8.50.
Investors are primarily focused on the commercial adoption of the RenovoCath device, specifically the expansion of active commercial centers toward the company's year-end target of 36 locations.
This report follows the major milestone of completing patient enrollment for the pivotal Phase 3 TIGeR-PaC trial in pancreatic cancer, which has bolstered analyst optimism for the TAMP platform.
With management recently raising full-year guidance, the market is looking for evidence that quarterly sales growth can maintain its triple-digit year-over-year pace.